LARUSSA, Tiziana
 Distribuzione geografica
Continente #
NA - Nord America 1.557
AS - Asia 1.103
EU - Europa 710
SA - Sud America 173
AF - Africa 17
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
Totale 3.577
Nazione #
US - Stati Uniti d'America 1.493
SG - Singapore 457
CN - Cina 290
IT - Italia 236
BR - Brasile 137
DE - Germania 135
IN - India 123
GB - Regno Unito 106
VN - Vietnam 82
FI - Finlandia 69
SE - Svezia 56
CA - Canada 44
IR - Iran 38
NL - Olanda 25
HK - Hong Kong 21
TR - Turchia 19
AR - Argentina 16
RU - Federazione Russa 14
MX - Messico 13
TW - Taiwan 11
AU - Australia 10
FR - Francia 10
PL - Polonia 10
BD - Bangladesh 9
UA - Ucraina 8
ID - Indonesia 7
IQ - Iraq 7
EC - Ecuador 6
RO - Romania 6
UZ - Uzbekistan 6
ES - Italia 5
IL - Israele 5
PY - Paraguay 5
ZA - Sudafrica 5
AT - Austria 4
CL - Cile 4
EU - Europa 4
PH - Filippine 4
PK - Pakistan 4
SA - Arabia Saudita 4
AL - Albania 3
CZ - Repubblica Ceca 3
JP - Giappone 3
LT - Lituania 3
MA - Marocco 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AO - Angola 2
BE - Belgio 2
BH - Bahrain 2
CH - Svizzera 2
CU - Cuba 2
EG - Egitto 2
HU - Ungheria 2
LB - Libano 2
PS - Palestinian Territory 2
RS - Serbia 2
UY - Uruguay 2
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GF - Guiana Francese 1
GR - Grecia 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
MG - Madagascar 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
QA - Qatar 1
VE - Venezuela 1
Totale 3.577
Città #
San Jose 263
Ashburn 152
Chandler 152
Singapore 142
Munich 114
Dallas 106
Chicago 90
London 86
Santa Clara 84
Hefei 79
Bengaluru 77
Lawrence 68
Princeton 68
Milan 66
Beijing 49
Helsinki 47
Wilmington 41
Ho Chi Minh City 31
Ottawa 30
Catanzaro 28
Des Moines 21
São Paulo 20
Hanoi 19
Hong Kong 19
Redwood City 19
Mumbai 18
Los Angeles 14
Turku 14
Mendicino 12
Shanghai 11
Guangzhou 10
Istanbul 9
New York 9
Praia A Mare 9
Rome 9
Boardman 8
Phoenix 8
The Dalles 8
Collegeville 7
Orem 7
Pune 7
Tehran 7
Chennai 6
Cittanova 6
Redmond 6
Shenzhen 6
Warsaw 6
Brooklyn 5
Curitiba 5
Da Nang 5
Hanover 5
Jyväskylä 5
Montreal 5
Norwalk 5
Rio de Janeiro 5
San Francisco 5
Belo Horizonte 4
Boston 4
Brasília 4
Clearwater 4
Horia 4
Santo André 4
Selargius 4
Silea 4
Taipei 4
Bade District 3
Bari 3
Benevento 3
Bratislava 3
Campinas 3
Cape Town 3
Charlotte 3
Council Bluffs 3
Dhaka 3
Frankfurt am Main 3
Fremont 3
Jiaxing 3
Kahramanmaraş 3
Karachi 3
Mexico City 3
Miguel Hidalgo 3
Nanjing 3
Naples 3
Paris 3
Quito 3
Rende 3
Riyadh 3
San Juan 3
Stockholm 3
São Bernardo do Campo 3
Tashkent 3
Tel Aviv 3
Vienna 3
Wuxi 3
Zabki 3
Amsterdam 2
Ankara 2
Ann Arbor 2
Atlanta 2
Baghdad 2
Totale 2.249
Nome #
Adverse drug reactions during biologic therapy in inflammatory disease: real life data from the pharmacovigilance project in the Calabria region 247
Dietary polyphenolsand non-alcoholic fatty liver disease 105
A Framework for Patient Data Management and Analysis in Randomised Clinical Trials 89
Efficacy of Mediterranean diet and antioxidants in overweight patients with non-alcoholic fatty liver disease. 79
Anxiety and Gastrointestinal Symptoms Related to COVID-19 during Italian Lockdown 76
Barriers And Facilitators In Conducting Clinical Trials In Inflammatory Bowel Disease: A Monocentric Italian Survey. 73
COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey 73
The role of gluten-free diet in nonalcoholic fatty liver disease development 73
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 69
Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview 68
Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. 63
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab 62
Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients 62
SARS-CoV-2 Spread Dynamics in Italy: The Calabria Experience 62
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 60
Enhanced expression of indole amine 2,3-dioxygenase (IDO) in Helicobacter pylori-infected human gastric muciosa downregulates interleukin (IL)-17 and upregulates IL-4 production. 59
Gut microbiota and non-alcoholic fatty liver disease 58
Effect of selective cyclooxygenase (Cox)-2 Inhibition and proton pump inhibitors (PPI) therapy on TH1 immune response in human gastric mucosa 56
Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. 55
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers 54
Helicobacter pylori and T Helper Cells: Mechanisms of Immune Escape and Tolerance 53
Enhanced expression of indoleamine 2,3-dioxygenase (IDO) in Helicobacter pylori-infected human gastric mucosa modulates TH1/TH2 patway and interleukin (IL)-17 production. 53
Decreased circulating interleukin-33 concentration in Helicobacter pylori-infected patients with peptic ulcer: Evaluation of its association with a cytokine gene polymorphism, gender of patients and bacterial virulence factor CagA 53
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 51
Bone mineralization in celiac disease 50
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers 49
Oleuropein decreases interleukin-17 and attenuates inflammatory damage in colonic mucosa from ulcerative colitis patients 47
Diminished circulating concentration of interleukin-35 in Helicobacter pylori-infected patients with peptic ulcer: Its association with FOXP3 gene polymorphism, bacterial virulence factor CagA, and gender of patients 46
Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: A systematic review 46
Enhanced activation of cyclooxygenase-2 down-regulates Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa 45
Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial 45
Effect of selective cyclooxygenase (COX)-2 inhibition and proton pump inhibitors (PPI) therapy on TH1 immune response in human gastric mucosa 44
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study 44
Crohn disease: Identification, diagnosis, and clinical management. 44
Self-Prescribed Dietary Restrictions are Common in Inflammatory Bowel Disease Patients and Are Associated with Low Bone Mineralization 43
Very low vitamin D level is an independent risk factor for bone demineralization in IBD patients 43
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients 42
Downregulation of Interleukin- (IL-) 17 through Enhanced Indoleamine 2,3-Dioxygenase (IDO) Induction by Curcumin: A Potential Mechanism of Tolerance towards Helicobacter pylori 42
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers 41
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers 41
Reduced bone mineral density is frequent in treated adult coeliac disease not with standing complete normalization of duodenal lesions. 40
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 39
Epidemiology of Helicobacter pylori infection: the Sorbo San Basile study. 39
Survey on alcohol consumption in a gastroenetrology outpatient center in southern Italy. 39
Trends and characteristics associated with dietary triggers and psychological distress in patients with irritable bowel syndrome: a cross-sectional study 38
Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed. 38
Normal Bone Mineral Density Associates with Duodenal Mucosa Healing in Adult Patients with Celiac Disease on a Gluten-Free Diet 37
Short-term Therapy with Celecoxib and Lansoprazole Modulates Th1/Th2 Immune Response in Human Gastric Mucosa 37
High prevalence of polymorphism and low activity of thiopurine methiltransferase in patients with inflammatory bowel disease. 37
Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease 37
Enhanced expression of indoleamine 2,3-dioxygenase in Helicobacter pylori-infected human gastric mucosa modulates Th1/Th2 pathway and interleukin 17 production 36
Living with inflammatory bowel diseases: patients’ perceptions and unmet needs from a single-center Italian survey 36
Potential role of fecal gluten immunogenic peptides to assess dietary compliance in celiac patients 36
Liver Cirrhosis Complications Management At The Emergency Department 36
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to standard pharmeceutical treatment: a double-blind, randomized, placebo-controlled study 35
Potential role of nutraceutical compounds in inflammatory bowel disease 35
Enhanced Expression of Indoleamine 2,3-Dioxygenase (IDO) in Helicobacter pylori-Infected Human Gastric Mucosa Modulates TH1/Th2 Pathway and Interleukin (IL)-17 Production. 34
SURVEY ON ALCOHOL CONSUMPTION IN A GASTROENTEROLOGY OUTPATIENT CENTER IN SOUTHERN ITALY 34
T cell subsets play an important role in the determination of the clinical outcome of Helicobacter pylori infection 34
The protective effects of resveratrol on ulcerative colitis via changing the profile of Nrf2 and IL-1β protein 34
Increased Indoleamine 2, 3-Dioxygenase expression modulates Th1/Th17/Th22 and Treg pathway in humans with Helicobacter Pylori-Infected gastric mucosa 34
No evidence of circulating autoantibodies against osteoprotegerin in treated celiac patients with low bone mineral density. 33
High Exposure, Spontaneous Clearance, and Low Incidence of Active Helicobacter pylori Infection: The Sorbo San Basile Study 33
Toll-like receptor 2: An important immunomodulatory molecule during Helicobacter pylori infection 32
Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives 32
Liver steatosis in celiac disease: the open door 30
Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey 30
Vitamin D down-regulates the expression of some Th17 cell-related cytokines, key inflammatory chemokines, and chemokine receptors in experimental autoimmune encephalomyelitis 30
No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease 29
OLEUROPEIN EXERTS ANTIOXIDANT ACTIVITY AND REDUCES THE EXPRESSION OF COX-2 AND PROINFLAMMATORY CYTOKINES IN CACO-2 CELLS AND COLONIC MUCOSA FROM ULCERATIVE COLITIS PATIENTS 29
Enhanced expression of indoleamine 2,3-dioxygenase in Helicobacter pylori-infected human gastric mucosa modulates Th1/Th2 pathway and interleukin 17 production 28
The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study 28
Beneficial effects of coffee in non-alcoholic fatty liver disease: a narrative review 28
High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. 27
From Pre- and Probiotics to Post-Biotics: A Narrative Review. 27
Refractory ulcerative colitis complicated by cytomegalovirus infection successfully treated with valganciclovir 26
Olive Tree Biophenols in Inflammatory Bowel Disease: When Bitter is Better 19
Totale 3.691
Categoria #
all - tutte 35.341
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.341


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 7 2 0
2021/2022258 8 7 14 49 17 4 10 48 22 26 37 16
2022/2023610 138 35 48 41 34 36 7 50 55 96 62 8
2023/2024290 69 20 25 16 10 75 6 15 27 2 9 16
2024/2025884 119 45 43 18 70 121 64 42 159 8 73 122
2025/20261.397 84 185 142 211 188 62 175 105 166 79 0 0
Totale 3.691